News and Blog / CMS NCD on Genomic Testing

When CMS initiated a national coverage analysis for NGS-based testing for advanced cancer on November 30, 2017, it stirred up a lot of debate among the leaders in precision medicine, and more specifically, PierianDx’s partner network of academic medical centers, cancer centers and health systems. For our customers, and essential community cancer centers that have CLIA-certified laboratories providing validated laboratory developed NGS-based tests, the proposed policy would supersede existing local coverage policies for most of those tests and limit Medicare beneficiaries’ access to a single test.